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Development, implementation
and outcomes of a quality
assurance system for the provision
of continuous renal replacement
therapy in the intensive care unit
Eloy F. Ruiz1, Victor M. Ortiz‑Soriano1, Monica Talbott1, Bryan A. Klein1,
Melissa L. Thompson Bastin2, Kirby P. Mayer3, Emily B. Price1, Robert Dorfman1,
Brandi N. Adams1, Lisa Fryman1, Javier A. Neyra1* on behalf of The University of Kentucky
CRRT Quality Assurance Group*
Critically ill patients with requirement of continuous renal replacement therapy (CRRT) represent
a growing intensive care unit (ICU) population. Optimal CRRT delivery demands continuous
communication between stakeholders, iterative adjustment of therapy, and quality assurance
systems. This Quality Improvement (QI) study reports the development, implementation and
outcomes of a quality assurance system to support the provision of CRRT in the ICU. This study was
carried out at the University of Kentucky Medical Center between September 2016 and June 2019.
We implemented a quality assurance system using a step-wise approach based on the (a) assembly
of a multidisciplinary team, (b) standardization of the CRRT protocol, (c) creation of electronic CRRT
flowsheets, (d) selection, monitoring and reporting of quality metrics of CRRT deliverables, and (e)
enhancement of education. We examined 34-month data comprising 1185 adult patients on CRRT
(~ 7420 patient-days of CRRT) and tracked selected QI outcomes/metrics of CRRT delivery. As a result
of the QI interventions, we increased the number of multidisciplinary experts in the CRRT team and
ensured a continuum of education to health care professionals. We maximized to 100% the use of
continuous veno-venous hemodiafiltration and doubled the percentage of patients using regional
citrate anticoagulation. The delivered CRRT effluent dose (~ 30 ml/kg/h) and the delivered/prescribed
effluent dose ratio (~ 0.89) remained stable within the study period. The average filter life increased
from 26 to 31 h (p = 0.020), reducing the mean utilization of filters per patient from 3.56 to 2.67
(p = 0.054) despite similar CRRT duration and mortality rates. The number of CRRT access alarms per
treatment day was reduced by 43%. The improvement in filter utilization translated into ~ 20,000
USD gross savings in filter cost per 100-patient receiving CRRT. We satisfactorily developed and
implemented a quality assurance system for the provision of CRRT in the ICU that enabled sustainable
tracking of CRRT deliverables and reduced filter resource utilization at our institution.
Continuous renal replacement therapy (CRRT) is the most common modality of renal replacement therapy
(RRT) utilized for managing critically ill patients with acute kidney injury (AKI) or end-stage kidney disease
(ESKD) who are hemodynamically unstable and with significant electrolyte/acid–base abnormalities or volume
overload1–3. Although only 6–10% of all patients in the intensive care unit (ICU) require acute RRT4–6, mortality
in these patients is high (50–60%)3,4,7. Thus, this is a vulnerable ICU population with a continuous need for an
organized approach to specialized care.

1

Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky,
Lexington, KY, USA. 2College of Pharmacy, Department of Pharmacy Practice and Science, University of
Kentucky, Lexington, KY, USA. 3Department of Physical Therapy, University of Kentucky, Lexington, KY, USA. *A
comprehensive list of consortium members appears at the end of the paper. *email: javier.neyra@uky.edu
Scientific Reports |

(2020) 10:20616

| https://doi.org/10.1038/s41598-020-76785-w

1
Vol.:(0123456789)

www.nature.com/scientificreports/

Characteristics

Total

Before QI interventions

After QI interventions

p-valuea
0.212

Total patients, n (%)

1185

483

702

AKI

986 (83.2)

394 (81.6)

592 (84.3)

ESKD

199 (16.8)

89 (18.4)

110 (15.7)

Age (years), mean ± SD

56.6 ± 14.2

55.9 ± 13.9

57.1 ± 14.4

0.147

Sex, male, n (%)

712 (60.1)

290 (60.0)

422 (60.1)

0.980

1087 (91.7)

441 (91.3)

646 (92.0)

Race, n (%)

0.254

White
Black

91 (7.7)

41 (8.5)

50 (7.1)

Other

7 (0.6)

1 (0.2)

6 (0.9)

Weight (kg), median [IQR]

90.9 [75.0–109.9]

90.8 [71.0–110.0]

91.0 [77.0–109.1]

0.229

Hospital LOS (days), median [IQR]

14.6 [5.7–28.8]

14.0 [6.0–27.9]

15.1 [5.4–29.4]

0.544

ICU LOS (days), median [IQR]

8.9 [3.8–19.2]

8.6 [3.8–15.5]

9.6 [3.9–20.7]

0.072

Mechanical ventilation (days), median [IQR]

4.0 [1.0–8.0]

3.5 [1.0–7.3]

4.0 [1.0–8.0]

0.278

Total CRRT days, median [IQR]

3.1 [1.4–7.0]

3.0 [1.2–6.5]

3.3 [1.6–7.4]

0.086

SOFA score at ICU admission, median [IQR]

12.0 [9.0–14.0]

12.0 [10.0–15.0]

12.0 [9.0–14.0]

0.198

SOFA score at CRRT initiation, median [IQR]

14.0 [11.0–16.0]

13.0 [11.0–15.0]

14.0 [11.0–16.0]

0.476

CCI score, median [IQR]

4.0 [2.0–7.0]

5.0 [3.0–7.0]

4.0 [2.0–6.0]

0.030

Alive

507 (42.8)

219 (45.3)

288 (41.0)

Dead

678 (57.2)

264 (54.7)

414 (59.0)

Discharge disposition, n (%)

0.167

Table 1.  Patient characteristics before and after implementation of CRRT quality improvement interventions.
Before QI interventions period included data from September 2016 to December 2017 (total of 16 months
before and during QI interventions). After QI interventions period included data from January 2018 to
June 2019 (18 months). AKI acute kidney injury, CCI Charlson comorbidity index, CRRTcontinuous renal
replacement therapy, ESKD end-stage kidney disease, ICU intensive care unit, LOS length of stay, QI quality
improvement, SOFA sequential organ failure assessment. a p-value of comparison for data before and after QI
interventions.

Regardless of substantial development in the technology and delivery of CRRT to critically ill patients, for
example, standardizing delivered average effluent flow rate to 20–25 ml/kg/h8, several aspects of CRRT delivery
are not fully standardized or do not have solid evidence-based f oundations9. Outstanding questions related to
provision of CRRT remain unanswered: patient selection, timing of CRRT initiation and discontinuation, volume management, anticoagulation and the role of high-volume hemofiltration and hemoadsorption1,3. These
factors hinder standardized provision of CRRT and result in wide heterogeneity of practice and in some cases,
suboptimal care for patients10,11. Current research focuses on addressing these uncertainties, however, information about the delivery process and quality of CRRT is still s carce12.
Optimal CRRT delivery demands continuous coordination and communication among multiple stakeholders,
iterative assessment and adjustment of therapy, and quality assurance systems11,13. A recent systematic review
identified potential quality indicators for CRRT classified into three categories: structure, process and o utcome10,
which included having a specialized care team, estimating the delivered and prescribed CRRT dose, measuring
the average filter life span, evaluating patient prognosis, among o
 thers2,10,13,14.
The success of a CRRT quality assurance system depends on team work dynamics and the selection of
adequate CRRT metrics which can be captured longitudinally and monitored systematically to identify problems
and generate opportunities for sustainable process i mprovement11,13,15. In this quality improvement (QI) study,
we report the development, implementation and outcomes of a quality assurance system to support the provision
of CRRT to adult patients in the ICU.

Results

Patient characteristics. We examined our 34-month experience comprising 1185 adult patients on CRRT

(~ 7420 patient-days of CRRT). As shown in Table 1, overall demographic and clinical data before and after
QI interventions were comparable. There were no differences in 12 out of 13 clinical characteristics reflecting
demographics, AKI status or acuity of illness parameters (e.g. SOFA score). The Charlson Comorbidity Index
(CCI) was slightly lower in patients examined after the QI interventions (4.0 vs. 5.0 before the QI interventions,
p = 0.030).

Quality improvement metrics. Data related to the selected CRRT QI metrics before and after QI interventions are shown in Table 2. To better visualize the trajectory of these metrics after the QI interventions, the
18-month data following QI interventions were subdivided into three 6-month periods.
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After QI interventions
CRRT QI metrics

Before QI interventions

Jan–Jun 2018

Jul–Dec 2018

Jan–Jun 2019

p-valuea

CRRT modality (CVVHDF), %

92.4%

95.1%

96.6%

100.0%

< 0.001

Anticoagulation (RCA), %

No data

23.1%

24.7%

39.5%

< 0.001

Total RCA/RCA-CRRT hours, mean ± SD

No data

0.62 ± 0.30

0.68 ± 0.27

0.73 ± 0.26

0.004

Delivered effluent dose (ml/kg/h),
mean ± SD

30.50 ± 4.18

27.67 ± 2.07

28.17 ± 1.83

30.33 ± 3.14

0.939

Delivered/prescribed effluent dose,
mean ± SD

0.88 ± 0.07

0.88 ± 0.02

0.88 ± 0.01

0.90 ± 0.02

0.487

Filter life span (hours), mean ± SD

26.00 ± 3.16

30.17 ± 4.96

31.00 ± 2.83

31.17 ± 3.31

0.020

Filters per patient, mean ± SD

3.56 ± 0.78

2.90 ± 0.87

2.75 ± 0.50

2.67 ± 0.64

0.054

CRRT access alarms per treatment day,
mean ± SD

2.95 ± 1.02

2.02 ± 0.64

1.63 ± 0.20

1.68 ± 0.50

0.021

Total filter cost per 100-patient (USD) ± SD

80,010 ± 17,519

65,173 ± 19,614

61,744 ± 11,287

59,876 ± 14,292

0.054

Table 2.  Selected CRRT metrics before and after implementation of CRRT quality improvement interventions.
The period before QI interventions included data from September 2016 to February 2017 (6 months). CRRT
continuous renal replacement therapy, CVVHDF continuous veno-venous hemodiafiltration, RCAregional
citrate anticoagulation, USD United States dollars. a p-value of comparison for data before QI interventions and
from the last 6 months after QI interventions (Jan 2019–Jun 2019). If data before QI interventions were not
available, data from the first 6 months after QI interventions (Jan 2018–Jun 2018) were used as reference.

Phase I: Team development and protocol standardization (March 2017–May 2017)
(a) Assembly of a multidisciplinary team

Nephrologists, intensivists, ICU nurses, pharmacists, dieticians,
physical therapists, technicians, bioinformaticians, ICU managers,
supply chain, management and administration personnel

(b) Standardization of the CRRT protocol tailoring institutional
logistics and needs

CVVHDF modality, RCA protocol (anticoagulant citrate dextrose
form A), customized order set (prescription entry) in the EHR; use
of a non-tunneled temporary dialysis catheter (15–20 cm long, 12–13
French) in the right internal jugular as the preferred CRRT vascular
access site

Phase II: Systematic tracking of CRRT deliverables (June 2017–September 2017)
(c) Creation of electronic CRRT flowsheets

Automated data extraction from the intakes and outputs flowsheet,
automated transfer of machine data (e.g. fluid removal, machine pressures) and embedded calculations for suggested hourly fluid removal
according to prescription

(d) Selection, monitoring and reporting of CRRT QI metrics

Ten QI metrics under 2 domains (structure and process) and 3 subdomains (provider, prescription and performance). Economic savings
was also included as a QI metric

Phase III: Training and teaching (October 2017–December 2017)

(e) Enhancement of education to clinicians and ICU nurses

ICU nurse education
New user education (eighteen 4-h sessions per year) on CRRT
prescription, protocols and technical aspects of the machine including
circuit and filter setup, alarms management, electronic CRRT charting, among others
Super user education (six 5-h sessions per year) on CRRT deliverables
and in-depth review of the CRRT machine, protocols and QI activities
Validator education (twelve 1-h sessions per year) on skills to verify
CRRT competency of other ICU nurses
Clinician education
Tailored for residents, fellows and Faculty. Two introductory sessions
and four advanced sessions per year

Table 3.  Summary of the three CRRT quality improvement intervention phases. CRRTcontinuous renal
replacement therapy, CVVHDF continuous veno-venous hemodiafiltration, EHR electronic health records,
ICU intensive care unit, QI quality improvement, RCAregional citrate anticoagulation.

Quality domain: structure. Regarding the provider subdomain, we increased our initial CRRT team from

1 clinician champion, 1 nurse educator and 77 CRRT Super Users (ratio of Super Users to total ICU nurses: 0.13)
in 2017 to a specialized multidisciplinary CRRT team constituted by 4 clinician champions (2 nephrologists and
2 intensivists), 3 nurse educators, 1 CRRT QI officer, 130 CRRT Super Users (ratio of Super Users to total ICU
nurses: 0.21), 2 dieticians, 2 physical therapists, 1 pharmacist, and 2 bioinformaticians (Supplementary Fig. S1).
Likewise, we provided instruction to our ICU nurses and clinicians to achieve a continuum of education and
training as detailed in Table 3.
In relation to the prescription subdomain, we improved adherence to the use of continuous veno-venous
hemodiafiltration (CVVHDF) from 92.4% to 100% (p < 0.001). The percentage of patients using regional citrate
anticoagulation (RCA) also significantly increased from 23.1% (January–June 2018) to 39.5% (January–June
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Figure 1.  Selected CRRT performance metrics before and after quality improvement interventions: (a) mean
number of filters used per patient (blue) and mean total hours of filter life (orange); (b) mean number of CRRT
access alarms per treatment day. CRRTcontinuous renal replacement therapy.
2019) (p < 0.001); and from those patients, the average ratio of the hours a patient had RCA by the total hours
the same patient was on CRRT also increased from 0.62 to 0.73 (p = 0.004). There were no data pertaining to
the period before QI interventions for these two RCA-related QI metrics (Table 2). It is important to note that
in our program we commonly use RCA vs. no anticoagulation for CRRT, and we seldom use systemic heparin
unless the patient has other specific indications for systemic anticoagulation (e.g., venous thromboembolism).

Quality domain: process. When assessing the performance subdomain, the delivered CRRT effluent dose
(ml/kg/h) remained stable (30.50 vs. 30.33; p = 0.939) as well as the ratio of delivered/prescribed CRRT effluent
dose (0.88 vs. 0.90; p = 0.487) (Table 2). The average filter life increased from 26 to 31 h (p = 0.020), reducing
the mean utilization of filters per patient from 3.56 to 2.67 (p = 0.054) (Fig. 1 and Table 2) despite similar CRRT
duration (median 3.0 vs. 3.2, p = 0.194) and mortality rates (54.7% vs 56.7%, p = 0.612) when comparing the
periods before QI interventions and the last 6 months post-intervention (January–June 2019). Also, the number
of access alarms per treatment day was reduced by 43% (p = 0.021) (Fig. 1, Table 2).
Economic savings. The improvement in filter utilization translated into ~ 20,000 USD gross savings in filter
cost per 100-patient receiving CRRT (p = 0.054) (Table 2, Fig. 2).
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Figure 2.  Gross filter cost per 100-patient receiving CRRT before and after quality improvement interventions.

Discussion

Critically ill patients requiring CRRT should receive their treatment in a safe, consistent and high-quality
manner16. Previous QI studies in the CRRT population have focused on the formation of a specialized CRRT
team17,18 and the creation of educational programs19–21 to improve the provision of CRRT in the ICU. Others
have conducted interventions to optimize specific CRRT deliverables such as the delivered effluent d
 ose12,17,22,
the achievement of daily fluid removal g oals12, as well as increasing filter l ife12,20,21, or decreasing unplanned filter
changes12 and total CRRT d
 owntime17,18. Our group has also reported QI interventions for patients on CRRT
such as early rehabilitation and physical a ctivity23 and the management of severe hyponatremia with customized
solutions24. In this manuscript, we report the development, implementation and outcomes of a quality assurance
system to support the provision of CRRT in the ICU at our institution. It is important to highlight that patient
demographics and clinical parameters before and after the QI interventions were comparable with the only exception of the CCI score. Further, preconditions such as type of CRRT machine (Prismaflex), filter (HF1400) and
catheter (Trialysis) remained unchanged throughout the study period, allowing the comparison of the selected
CRRT metrics before and after QI interventions. Our report adheres to the Standards for Quality Improvement
Reporting Excellence (SQUIRE 2.0) guidelines and r ecommendations25.
The QI intervention lasted 10 months and was carried out in a step-wise fashion. Several key elements to its
successful implementation should be noted. First, the robust multidisciplinary collaboration between nephrologists, intensivists, ICU nurses, pharmacists and other healthcare professionals provided unique perspectives,
expertise, and helped to achieve a common mindset for the provision of CRRT in the ICU (Supplementary
Fig. S1). Second, the standardization of the CRRT protocol on the use of CVVHDF and RCA helped to reduce
variability of CRRT delivery and maximize the providers’ competence as education was focused on a specific
order set. Additionally, well-defined catheter characteristics and CRRT vascular access site helped to acquire
dexterity on its handling and functionality. Third, the creation of the electronic CRRT flowsheets allowed for
automated machine data transfer and embedded calculations supporting data entry for ICU nurses. Furthermore,
as this tool is available on-line within the electronic health record (EHR), the clinical and QI teams were able to
track CRRT delivery at any given moment. Fourth, the selection, monitoring and reporting of specific CRRT QI
metrics facilitated the assessment of interim results, identification of areas for improvement, and modifications
or reinforcement of good practices for better outcomes. Lastly, the establishment of a dedicated CRRT education
team made it possible to continuously train and improve the workforce’s knowledge and skills. Of note, some QI
metrics exhibited an early trend of continuous improvement while others only showed a significant improvement by the last 6 months post-implementation (e.g., use of RCA anticoagulation). The latter reflects real-world
hindrances in CRRT delivery, which require a sustainable process of QI monitoring, continuous education, and
tailored interventions to achieve the desired QI goals.
By the end of June 2019, we increased the number of multidisciplinary experts comprising the CRRT QI
team and ensured a continuum of education to healthcare professionals involved in CRRT delivery. This was a
major milestone because every CRRT program requires a diverse, strong and engaged core responsible for the
provision of high-quality and cost-effective CRRT11,26,27. Some institutions have described weak collaboration
between stakeholders (e.g. nephrologists and intensivists), not enough training for their healthcare professionals
or lack of CRRT QI initiatives27. Fortunately, we were able to develop a specialized CRRT team in addition to
dedicated classes for ICU nurses and clinicians held many times per year (Table 3), plus approachable educators
to solve questions and concerns regarding CRRT delivery in a timely manner.
Regarding CRRT modality and anticoagulation, we were able to improve consistency of care and reduce
CRRT variability by standardizing the CRRT protocol according to our local logistics and expertise. We achieved
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100% CVVHDF use, ~ 40% RCA use with > 70% of the CRRT time on RCA by the end of the study period. No
other form of anticoagulation is routinely used when performing CRRT in our program unless the patient has
specific indications for systemic anticoagulation. Even though we increased the CVVHDF use to the maximum,
adherence to the citrate protocol should be further improved as evolving evidence suggests prolonged filter life
span with RCA u
 se28–31. Challenges to widespread implementation of RCA use may be related to patient-specific
factors (e.g., impaired liver metabolism under certain shock scenarios), feasibility of protocols for citrate titration
and calcium supplementation, and clinician and nursing staff logistics and training. Furthermore, one should
note that there is no evidence to support any specific CRRT modality over the other but reducing practice variability may prevent operator-related errors and therefore we selected a single modality of CRRT (e.g., CVVHDF)
for our program.
CRRT dose is a dynamic metric that must be adjusted to the changing clinical needs of the patient9. According to Kidney Disease Improving Global Outcomes (KDIGO), it is recommended to achieve a delivered average
CRRT effluent flow rate of 20–25 ml/kg/h, but ~ 30 ml/kg/h could be prescribed as interruptions, the use of prefilter solutions and reductions in membrane permeability decrease the delivered dose8. Furthermore, the Acute
Disease Quality Initiative (ADQI) group stated the average ratio of the effective delivered effluent dose relative
to prescribed dose should be > 0.8032. Our results showed that the delivered CRRT effluent dose (~ 30 ml/kg/h)
and the delivered/prescribed effluent dose ratio (~ 0.89) did not significantly change after QI interventions and
remain adherent to guideline recommendations.
In relation to filter life, we managed to increase it from 26 to 31 h and decrease mean utilization of filters
per patient from 3.56 to 2.67 despite no change in CRRT duration or mortality rates. Current evidence suggests
optimization of circuit patency and filter performance primarily depends on anticoagulation practices (favoring RCA use)30,31, but there are still insufficient data to determine if preconditions (filter, vascular access site,
catheter type) or patient characteristics (mechanical ventilation, SOFA score, calcium levels, platelet count, red
blood cell transfusion, fibrinogen) may alter filter l ife33. Likewise, education to ICU nurses about filter management appears to increase its life s pan20,21, but evidence is still limited and more research is needed33. Therefore,
it is important to document reasons for filter change and evaluate filter life span accordingly. As described by
Mottes et al., there are planned filter changes (e.g., filter expiration, decision to stop therapy) and unplanned filter
changes (e.g., cardiac arrest, emergent test or procedure, clotted circuit)20. We are currently working to improve
our data collection to better examine specific reasons of filter change.
With respect to the number of access alarms per treatment, we reduced them by 43%. Although we did not
assess for correlation with access placement site due to data availability, we hypothesize this could be a result of
the iterative instruction to clinicians on proper catheter election and placement, in addition to enhanced education for ICU nurses on access alarm recognition, management and resolution.
The cost of CRRT relies on ICU nurse staffing salary, dialysate and/or replacement fluids, anticoagulation and
extracorporeal circuit (including filter) costs34. It was estimated that a 24-h CVVHDF treatment costs ~ $1060
USD (excluding anticoagulation), but prices may vary from center to center35. After the described CRRT QI
interventions, we improved our resource utilization (average filter life span and average total number of filters
used per patient) and rendered ~ 20,000 USD gross savings in filter cost per 100-patient receiving CRRT at our
institution. It is important to emphasize that these savings are only related to filter cost and does not account for
other CRRT-related costs such as fluids, anticoagulation, monitoring or staffing salary.
Our study has some limitations to consider when interpreting the results. First, given the multifaceted quality
assurance implementation, we cannot prove which specific QI intervention impacted any given outcome (e.g.,
RCA use vs. nurse education for improvement in filter life). Further, residual confounding is possible given the
observational nature of this QI study. Second, this work was primarily planned to improve CRRT local care
according to the characteristics and logistics of our institution, therefore our approach may not be applicable to
other centers. Likewise, additional monitoring may be necessary to evaluate the sustainability of these results
over time. However, we established a framework for quality assurance, analyzed a large number of patients
(~ 7420 patient-day of CRRT) and made several measurements of CRRT QI metrics accepted in our scientific
community to compare outcomes before and after QI interventions. Future directions include expanding our
data collection to have additional tracking of CRRT QI metrics (e.g. intended vs. unintended filter changes,
medication adjustments, fluid management, small solute clearance, adverse events, catheter dysfunction) as
proposed by Rewa et al.16 and o
 thers12–14. Finally, this work exemplifies the ability to nurture collaborative and
quality improvement work in the ICU.
Our findings indicate that through developing a multidisciplinary CRRT team, standardizing CRRT protocols, integrating machine/EHR data, and reinforcing education, we were able to improve adherence to protocols,
confidently and sustainably track CRRT delivery and reduce filter resource utilization at our institution. Additional studies are needed to confirm these results and the impact of these QI initiatives on processes of care and
patient-centered outcomes.

Methods
Setting.

The University of Kentucky (UK) Albert B. Chandler Hospital is a 945-bed acute care hospital with
more than 37,000 admissions and approximately 2500 medical ICU admissions per y ear23,24. The Nephrology
ICU consultation team (consisting of one attending, one fellow, and one resident or advanced practitioner)
provides diagnostic and therapeutic services for patients with AKI and ESKD requiring CRRT in the ICU. The
provision of CRRT leans on a multidisciplinary approach, including intensivists, ICU nurses, pharmacists and
many other specialists. We perform CRRT for approximately 500 patients annually, corresponding to ~ 3200
CRRT patient-day per year.
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Figure 3.  Study periods and phases of quality improvement interventions. CRRTcontinuous renal replacement
therapy.
This QI study describes the development, implementation and outcomes of a quality assurance system to
support the provision of CRRT to adult patients in the ICU. This QI study was approved by the University of
Kentucky Institutional Review Board (IRB) of the Office of Research Integrity (17-0444-P1G). Requirement for
informed consent was waived by the IRB (https://www.research.uky.edu/office-research-integrity). All methods
were carried out in accordance with relevant guidelines and regulations.

Implementation. We developed and implemented a quality assurance system using a step-wise approach in
3 phases (intervention period, total of 10 months) (Fig. 3). The Phase I (3 months) consisted in the (a) assembly
of a multidisciplinary team and the (b) standardization of the CRRT protocol tailoring institutional logistics and
needs. The Phase II (4 months) involved the (c) creation of electronic CRRT flowsheets (Supplementary Fig. S2)
and the (d) selection, monitoring and reporting of CRRT quality metrics. Finally, the Phase III (3 months)
focused on the (e) enhancement of education to clinicians and ICU nurses.
We also established 3 study periods with the purpose of evaluating the impact of our intervention (Fig. 3).
These periods were defined according to data availability before the intervention and the step-wise completion
of milestones during the intervention phases. These periods consisted of: (1) before intervention (September
2016 to February 2017, 6 months); (2) intervention (March 2017 to December 2017, 10 months); and (3) after
intervention (January 2018 to June 2019, 18 months).
Intervention. The 10-month intervention was carried out from March 2017 to December 2017 in 3 stepwise phases described in Table 3. Team development and protocol standardization (Phase I) allowed the establishment of the multidisciplinary quality assurance team (Supplementary Fig. S1) which reached consensus for
CRRT protocols (modality, dose, access, and anticoagulation) based on revision of current guidelines, evidencebased practices, institutional logistics and local expertise. For the selection of CRRT QI metrics to monitor
CRRT delivery (Phase II), we adapted via consensus the quality control system proposed by Joannes-Boyau
et al.13 including structure metrics encompassing the CRRT provider (e.g., specialized team, education program)
and the CRRT prescription (e.g. modality, prescribed dose, anticoagulation); and process (performance) metrics
(e.g., delivered dose, filter life span, access alarms). A total of 11 CRRT QI metrics (study outcomes) under the
domains of structure and process, and 3 subdomains (provider, prescription and performance) in addition to
economic savings specific to filter use were selected for this study and are described in detail in Table 4. Preconditions such as type of CRRT machine, filter and catheter were not changed throughout the study period. For
training and teaching (Phase III), we conducted dynamic monthly assessments of learning needs to tailor teaching activities for ICU nurses (New and Super Users) and clinicians. This was done by auditing CRRT charting,
assessing machine specific performance data, and making rounds in the ICUs (Super Users were available in
both day and night shifts). Clinical duties were not compromised as the QI officer and leadership of the program
have protected time for these activities. Furthermore, physicians, ICU nurses and other healthcare professionals
were invited to attend bi-monthly QI meetings in order to voice all concerns they were experiencing as well as to
conduct an iterative assessment of the program.
Study data. Data from all adult patients (≥ 18 years old) receiving CRRT in the ICU during the study period
were analyzed. Demographic and clinical data were collected by automated digital extraction from the EHRs
through a flexible dashboard (Tableau, Supplementary Fig. S3), which allowed data to be downloaded as spreadsheets or graphics for review and further analysis. Data extraction was validated through individual review of
EHRs. Performance data from CRRT machines were extracted from accessing individual machine data cards
during the study period.
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Quality domain: structure
Provider
1. Specialized CRRT team

The number of multidisciplinary experts that constitutes the CRRT QI team

2. Education and training program

The number of education sessions for clinicians, ICU nurses and other healthcare professionals

Prescription
3. CRRT modality

The percentage of the total CRRT treatments that used CVVHDF as the main modality established by protocol

4. Anticoagulation

The percentage of the total CRRT treatments that used RCA

5. Total RCA/RCA-CRRT hours

The average total RCA hours divided by total CRRT hours in patients that used RCA

Quality domain: process
Performance
6. Delivered effluent dose

The average delivered CRRT effluent flow rate (ml/kg/h)

7. Delivered vs. prescribed effluent dose

The average delivered CRRT effluent dose divided by prescribed dose

8. Filter life span

The average time (in hours) of individual filter utilization

9. Filters per patient

The average total number of filters used divided by the total number of patients on CRRT

10. CRRT access alarms

The average number of CRRT access alarms per treatment day, reflecting catheter malfunction
(high venous pressure in return line or low arterial pressure in access line)

11. Economic savings

The average gross total filter cost per 100-patient receiving CRRT

Table 4.  Description of selected CRRT quality improvement metrics for this study. CRRTcontinuous renal
replacement therapy, CVVHDF continuous veno-venous hemodiafiltration, ICU intensive care unit, QI quality
improvement, RCAregional citrate anticoagulation.

Statistical analysis. Categorical variables are expressed as counts and percentages. Continuous variables

are reported as mean and standard deviation (SD), or median and interquartile range (IQR) according to data
distribution. A chi-square test or Fisher’s exact test was used to compare categorical variables when appropriate. Continuous variables with a normal distribution were compared using an independent Student t-test; in
contrast, variables not exhibiting a normal distribution were compared using the Mann–Whitney U test. All
statistical analyses were performed using SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0. Armonk,
NY: IBM Corp). A two-tailed p < 0.05 was considered statistically significant.

Ethics approval and consent to participate. This QI study was approved by the University of Kentucky

Institutional Review Board (IRB) of the Office of Research Integrity (17-0444-P1G). Requirement for informed
consent was waived by the IRB (https://www.research.uky.edu/office-research-integrity). All methods were carried out in accordance with relevant guidelines and regulations.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on
reasonable request.
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